Rozman C, Montserrat E, Viñolas N, Urbano-Ispizua A, Ribera J M, Gallart T, Compernolle C
Postgraduate School of Hematology Farreras Valenti, Hospital Clínic i Provincial, Barcelona, Spain.
Blood. 1988 May;71(5):1295-8.
Ten previously untreated patients with early B cell chronic lymphocytic leukemia (B-CLL) (seven in Rai's stage 0, three in stage I) were given recombinant alpha 2-interferon (alpha 2IF) (2 X 10(6) U/m2 intramuscularly three times a week for a minimum of 14 weeks) to assess its effectiveness. All patients were evaluable for response to therapy and toxicity. No complete response was achieved. In all cases a definite, although transient reduction in the absolute number of peripheral blood lymphocytes was observed. In eight patients an increase in the absolute number of granulocytes was detected. None of the patients experienced severe hematologic toxicity. Fatigue, malaise, and fever were the more common side effects, but all patients were able to finish their treatment as planned. The results of this pilot study suggest that low doses of recombinant alpha 2-IF have some activity in early and previously untreated B-CLL and that further studies of IF effectiveness in B-CLL seem warranted.
十名先前未经治疗的早期B细胞慢性淋巴细胞白血病（B-CLL）患者（七名处于Rai分期0期，三名处于I期）接受了重组α2干扰素（α2IF）治疗（2×10⁶U/m²，每周三次肌肉注射，至少持续14周）以评估其疗效。所有患者均可评估对治疗的反应及毒性。未获得完全缓解。在所有病例中，均观察到外周血淋巴细胞绝对数有明确的、尽管是短暂的减少。在八名患者中检测到粒细胞绝对数增加。没有患者出现严重血液学毒性。疲劳、不适和发热是较常见的副作用，但所有患者都能按计划完成治疗。这项初步研究的结果表明，低剂量重组α2-IF对早期未经治疗的B-CLL有一定活性，并且似乎有必要进一步研究IF在B-CLL中的疗效。
